Neonatal & Early Infantile Epileptic Encephalopathies

The neonatal and early infantile epileptic encephalopathies represent the most severe end of the epilepsy spectrum, with seizure onset in the first months of life, profoundly abnormal EEG patterns, and devastating neurodevelopmental consequences. Under the ILAE 2022 classification, these disorders are now encompassed under the term developmental and epileptic encephalopathies (DEEs)—recognizing that both the underlying etiology and the epileptic activity itself contribute to neurodevelopmental impairment. Advances in next-generation sequencing have revealed that many of these syndromes are caused by single-gene variants, with over 50% of early-onset DEEs now receiving a molecular diagnosis. This has transformed the approach from purely descriptive electroclinical classification toward precision medicine—where the specific genetic etiology directly informs treatment selection, prognostic counseling, and eligibility for emerging gene-targeted therapies. Crucially, several treatable metabolic causes (pyridoxine-dependent epilepsy, PNPO deficiency) present within this group, making urgent metabolic workup and empiric vitamin trials mandatory in any neonate with refractory seizures.

ILAE 2022 Classification: Developmental and Epileptic Encephalopathies

The ILAE 2022 position statement on epilepsy syndromes with onset in neonates and infants introduced important terminological and conceptual changes that directly affect the classification of these syndromes:

• Developmental encephalopathy (DE): Neurodevelopmental impairment is caused by the underlying etiology (e.g., a genetic variant affecting brain development) independently of epileptic activity
• Epileptic encephalopathy (EE): The epileptic activity itself (seizures, interictal discharges) causes neurodevelopmental impairment or regression beyond what the underlying etiology would produce alone
• Developmental and epileptic encephalopathy (DEE): Both mechanisms coexist—the majority of neonatal-onset syndromes fall into this combined category
• The term "early infantile DEE" now encompasses the previously distinct syndromes of Ohtahara syndrome and early myoclonic encephalopathy, though many clinicians continue to use the older eponyms for phenotypic specificity
• Self-limited syndromes: "Benign" has been replaced with "self-limited"; "familial" is included when a family history is present (e.g., self-limited familial neonatal epilepsy replaces benign familial neonatal seizures)

Ohtahara Syndrome (Early Infantile Epileptic Encephalopathy)

Overview

Ohtahara syndrome, also known as early infantile epileptic encephalopathy (EIEE), is the earliest-onset and one of the most severe epileptic encephalopathies, presenting within the first 3 months of life—typically within the first 10 days. It is defined by tonic spasms (the hallmark seizure type) and a burst-suppression pattern on EEG that is present in both wakefulness and sleep.

• Onset: First 3 months of life (often first 10 days); the earliest of the epileptic encephalopathies
• Seizure types: Tonic spasms (brief, 1–10 seconds, often in clusters) are the hallmark; may also have focal seizures; myoclonic seizures are notably absent or rare—a key distinction from EME
• EEG: Burst-suppression—high-amplitude bursts (150–350 μV) of polyspikes and slow waves alternating with periods of suppression (3–5 seconds); present in BOTH wakefulness and sleep (unlike EME)
• Etiology: Structural causes predominate (cortical dysplasia, hemimegalencephaly, Aicardi syndrome, porencephaly); genetic causes include STXBP1, ARX, KCNQ2, SCN2A, BRAT1
• Evolution: Approximately 75% evolve to West syndrome (infantile spasms with hypsarrhythmia) by 3–6 months, then may further evolve to Lennox-Gastaut syndrome
• Prognosis: Extremely poor; profound intellectual disability; high mortality in infancy; seizures are drug-resistant to all standard ASMs

Early Myoclonic Encephalopathy (EME)

Overview

Early myoclonic encephalopathy (EME) is a neonatal epileptic encephalopathy characterized by erratic, fragmentary myoclonus beginning in the first month of life, with a burst-suppression EEG pattern more prominent during sleep. In contrast to Ohtahara syndrome, which is more often structural in origin, EME is predominantly caused by inborn errors of metabolism.

• Onset: First month of life; often in the first week
• Seizure types: Erratic, fragmentary myoclonus (involving face, limbs, fingers individually—not synchronized) is the HALLMARK; may progress to focal seizures and late tonic spasms; myoclonus may be subtle and easily overlooked
• EEG: Burst-suppression more prominent in sleep; may show a more discontinuous pattern in wakefulness without classic burst-suppression; suppression periods tend to be longer than in Ohtahara
• Etiology: Metabolic causes predominate—nonketotic hyperglycinemia (glycine encephalopathy, GLDC/AMT), pyridoxine-dependent epilepsy (ALDH7A1), pyridox(am)ine 5′-phosphate oxidase deficiency (PNPO), molybdenum cofactor deficiency, sulfite oxidase deficiency, organic acidurias (propionic acidemia, methylmalonic acidemia)
• Evolution: Does NOT typically evolve through the Ohtahara → West → LGS sequence; myoclonus persists; infantile spasms may develop but hypsarrhythmia is uncommon
• Prognosis: Catastrophic; approximately 50% die within weeks to months; survivors have profound disability; treatable metabolic causes (pyridoxine dependency) may respond if identified early

Ohtahara Syndrome vs. Early Myoclonic Encephalopathy

KCNQ2-Related Developmental and Epileptic Encephalopathy

KCNQ2 encodes the KV7.2 voltage-gated potassium channel subunit, which forms heteromeric channels with KV7.3 (encoded by KCNQ3) to generate the M-current—a critical regulator of neuronal excitability near the resting membrane potential. KCNQ2 pathogenic variants produce a remarkable phenotypic spectrum, ranging from the benign self-limited familial neonatal epilepsy to severe DEE. The genotype-phenotype relationship is determined by the functional consequence of the variant.

• Onset: First week of life; typically within the first 3 days
• Seizure types: Tonic seizures (asymmetric or bilateral); may also have focal clonic seizures and apneic episodes; seizures may be very frequent (dozens per day)
• EEG: Burst-suppression or multifocal epileptiform discharges; background may be markedly discontinuous; the burst-suppression pattern in KCNQ2-DEE can mimic Ohtahara syndrome
• Genetics: De novo KCNQ2 missense variants, typically in critical functional domains (pore region, voltage sensor, calmodulin binding domain); cause a dominant-negative effect—the abnormal protein interferes with normal KV7.2/KV7.3 channel function, which is more severe than simple haploinsufficiency
• Neurodevelopment: Moderate to severe intellectual disability; hypotonia evolving to spasticity; some patients have autistic features
• Prognosis: Seizures may improve or resolve over the first years of life in some patients, but neurodevelopmental impairment persists

Pyridoxine-Dependent Epilepsy

Pyridoxine-dependent epilepsy (PDE) is an autosomal recessive metabolic epilepsy caused by pathogenic variants in ALDH7A1, which encodes α-aminoadipic semialdehyde dehydrogenase (antiquitin). Deficiency of this enzyme in the lysine degradation pathway leads to accumulation of α-aminoadipic semialdehyde (α-AASA) and its cyclic form, piperideine-6-carboxylate (P6C), which inactivates pyridoxal 5′-phosphate (the active form of vitamin B6)—an essential cofactor for over 160 enzymes including glutamic acid decarboxylase (GAD), the enzyme that synthesizes GABA.

• Onset: Neonatal (most common, ~75%) or late-onset (up to 3 years); prenatal seizures may occur (in utero fetal movements)
• Seizure types: Prolonged seizures or status epilepticus refractory to standard ASMs; variable seizure types (tonic, clonic, myoclonic); burst-suppression may be present
• Diagnosis: Elevated urinary α-AASA (the most sensitive biomarker); elevated plasma pipecolic acid; confirmatory genetic testing of ALDH7A1; CSF neurotransmitter analysis may show low GABA
• Treatment: Dramatic, often immediate response to IV pyridoxine (100 mg bolus under EEG monitoring)—seizures may cease within minutes; lifelong pyridoxine supplementation (15–30 mg/kg/day in neonates, 200–500 mg/day in older children)
• Adjunctive therapy: Lysine-restricted diet and arginine supplementation may improve neurodevelopmental outcomes by reducing neurotoxic lysine metabolites
• Prognosis: Seizures are controlled with pyridoxine in the majority; however, ~75% have some degree of intellectual disability, particularly if treatment is delayed; early recognition and treatment (ideally within the first week) are associated with better neurodevelopmental outcomes

CDKL5 Deficiency Disorder

CDKL5 deficiency disorder (CDD) is an X-linked DEE caused by pathogenic variants in CDKL5 (cyclin-dependent kinase-like 5), a serine/threonine kinase critical for neuronal development, synapse formation, and dendritic morphogenesis. It was previously classified within the Rett syndrome spectrum but is now recognized as a distinct entity with unique clinical features.

• Onset: First 3 months of life (median onset ~6 weeks); earlier than classic Rett syndrome
• Seizure types: Hypermotor seizures (tonic-vibratory pattern) and tonic spasms are characteristic; epileptic spasms may develop; seizures may occur in prolonged sequences; status epilepticus is common
• EEG: Interictal EEG may be normal in the first months; progressive background slowing develops; multifocal epileptiform discharges; NO burst-suppression (unlike Ohtahara/EME)
• Clinical features beyond seizures: Severe intellectual disability; absent or minimal speech; stereotypic hand movements (midline wringing, mouthing—Rett-like); cortical visual impairment; hypotonia; GI dysfunction (constipation, reflux); dysautonomia; sleep disturbances
• Key distinction from Rett syndrome: Earlier seizure onset; no period of normal development followed by regression (regression is the hallmark of Rett); hand stereotypies are less prominent; MECP2 testing is negative
• Genetics: X-linked; CDKL5 variants; affects females predominantly (males with hemizygous variants have more severe phenotype); de novo in the vast majority
• Treatment: Seizures are profoundly drug-resistant; no single ASM has demonstrated consistent efficacy; cannabidiol (Epidiolex) showed modest benefit in open-label studies; ganaxolone (a neurosteroid, GABA-A receptor modulator) received FDA approval for CDD-associated seizures in patients ≥2 years based on the Marigold trial
• Emerging therapies: Gene replacement therapy (AAV-mediated CDKL5 delivery) is in early clinical trials; protein replacement strategies are under investigation

Epilepsy of Infancy with Migrating Focal Seizures

This rare but devastating syndrome, also known as migrating partial seizures of infancy, is characterized by near-continuous multifocal seizures that "migrate" from one cortical region to another, beginning in the first 6 months of life. The hallmark EEG finding is sequential, independent ictal activity arising from different cortical regions, often within the same prolonged seizure event.

• Genetics: KCNT1 (potassium sodium-activated channel, subfamily T, member 1) gain-of-function variants are the most common cause (~50%); also SCN1A, SCN2A, SLC25A22, PLCB1, TBC1D24, CHD2
• Onset: Peak onset ~3 months of age (range: first 6 months)
• Seizure types: Focal seizures with prominent autonomic features (facial flushing, apnea, cyanosis), eye deviation, and clonic activity; seizures migrate from hemisphere to hemisphere on EEG during the same prolonged event; episodes of status epilepticus are frequent
• EEG: Sequential involvement of independent cortical regions; ictal activity begins in one area, subsides, then emerges in a different area—a pathognomonic "migrating" pattern
• Treatment: Extremely drug-resistant; quinidine (a potassium channel blocker) has shown benefit in some KCNT1 cases by reducing the gain-of-function effect, though results are inconsistent and cardiac monitoring is mandatory; bromide has shown efficacy in some cases; ketogenic diet may provide partial benefit
• Prognosis: Severe; profound developmental impairment; high risk of severe neurologic disability and reduced life expectancy; seizure frequency may decrease with age but rarely remits

Self-Limited Neonatal and Infantile Epilepsy Syndromes

Self-Limited Familial Neonatal Epilepsy (BFNS/BFNE)

Self-limited familial neonatal epilepsy (formerly benign familial neonatal seizures) is an autosomal dominant channelopathy presenting with seizures in the first week of life that characteristically resolve spontaneously. It represents the benign end of the KCNQ2 phenotypic spectrum.

• Genetics: KCNQ2 (chromosome 20q; ~85% of families) or KCNQ3 (chromosome 8q); loss-of-function variants causing haploinsufficiency of the M-type potassium channel (KV7.2/KV7.3)
• Onset: Days 2–7 of life (classically "fifth day fits"); may begin as early as day 1
• Seizure types: Clonic and tonic seizures; may be focal or generalized; brief apneic episodes; seizures may occur in clusters; each seizure typically lasts 1–3 minutes
• EEG: Ictal: focal or multifocal discharges; a theta pointu alternant pattern (runs of 4–7 Hz theta with intermixed sharp waves that may alternate sides) may be seen; interictal EEG is often normal; burst-suppression or persistent slowing should NOT be present (their presence suggests KCNQ2-DEE rather than self-limited KCNQ2 epilepsy)
• Family history: Positive in most (autosomal dominant with ~85% penetrance)
• Prognosis: Seizures resolve spontaneously by 6 weeks in most; normal neurodevelopment is the rule; ~16% develop epilepsy later in life (often self-limited)

Self-Limited Familial Neonatal-Infantile Epilepsy (BFNIS)

• Genetics: SCN2A pathogenic variants (gain-of-function); autosomal dominant
• Onset: 2 days to 7 months of age (bridging the neonatal and infantile periods)
• Seizure types: Focal seizures, often with secondary generalization; brief, clustered events
• EEG: Normal interictal; focal ictal discharges
• Key feature: SCN2A gain-of-function variants in early-onset (<3 months) epilepsy are often responsive to sodium channel blockers (carbamazepine, phenytoin)—this is in direct contrast to later-onset SCN2A loss-of-function variants, where sodium channel blockers may worsen seizures
• Prognosis: Self-limited; seizures remit by 12 months in most; normal neurodevelopment

Self-Limited (Familial) Infantile Epilepsy (BFIS)

• Onset: 3–20 months of age (peak at 6 months)
• Genetics: PRRT2 (chromosome 16p11.2) is the most common gene; autosomal dominant; also SCN2A and SCN8A
• Seizure types: Clusters of brief focal clonic or focal-to-bilateral tonic-clonic seizures, often with eye deviation and head turning; each seizure lasts 2–5 minutes
• EEG: Normal interictal; focal parieto-occipital or temporal ictal onset
• Treatment: Responsive to oxcarbazepine (especially for PRRT2-related cases); NOT responsive to levetiracetam (which works through SV2A and the SNARE complex, whereas the PRRT2 protein interacts with SNAP25)
• Prognosis: Seizures remit after 3 years of age; normal neurodevelopment; excellent long-term outcome
• PRRT2-associated syndromes: The same PRRT2 variants can cause paroxysmal kinesigenic dyskinesia (PKD) in adolescence, or the combined infantile convulsions and choreoathetosis (ICCA) syndrome

Master Differential Diagnosis Table

Genetic Testing Approach

The genetic evaluation of a neonate with suspected epileptic encephalopathy should proceed in parallel with urgent metabolic testing and empiric vitamin trials. The ILAE Task Force on Clinical Genetic Testing (2022) recommends genetic testing for all patients with severe childhood-onset epilepsies, particularly the DEEs, as well as epilepsy plus intellectual disability or other neurodevelopmental comorbidities. Exome sequencing is now the recommended first-line genetic test.

Precision Therapy Based on Genetic Diagnosis

Knowledge of the specific genetic etiology enables mechanistically informed treatment selection in a growing number of neonatal DEEs. The effect of genetic diagnosis on management is substantial—studies report that genetic diagnosis leads to a change in medical management in over 70% of patients with epilepsy.

Treatment Algorithm for Refractory Neonatal Seizures

The following stepwise approach is recommended when a neonate presents with seizures refractory to initial management:

• Step 1 (immediate): Standard acute seizure management—phenobarbital loading dose (20 mg/kg IV); if seizures persist, additional 10 mg/kg boluses (up to total 40 mg/kg)
• Step 2 (within 24–48 hours if refractory): Empiric pyridoxine trial (100 mg IV under EEG monitoring); if no response within 10 minutes, repeat ×2; if still refractory, begin enteral PLP (30 mg/kg/day); concurrently trial folinic acid (5 mg/kg/day)
• Step 3 (in parallel): Urgent metabolic workup (plasma amino acids, urine organic acids, CSF amino acids with glycine ratio, α-AASA, pipecolic acid) AND genetic testing (rapid epilepsy gene panel or rapid exome sequencing); brain MRI
• Step 4 (guided by results): If KCNQ2 variant identified → carbamazepine/phenytoin; if KCNT1 variant → consider quinidine with cardiac monitoring; if metabolic etiology → specific treatment; if structural lesion → evaluate for surgery
• Step 5 (ongoing): If no etiology identified and seizures persist, consider broad-spectrum ASMs (levetiracetam, topiramate), ketogenic diet, and re-evaluate genetic/metabolic workup; periodic reanalysis of genetic data is recommended

Aicardi Syndrome

Aicardi syndrome is a rare neurodevelopmental disorder characterized by a classic triad of infantile spasms, agenesis of the corpus callosum, and chorioretinal lacunae. It occurs almost exclusively in females, consistent with X-linked dominant inheritance that is presumed lethal in males (the specific gene has not yet been identified).

• Classic triad: (1) Infantile spasms (onset 3–5 months), (2) agenesis or dysgenesis of the corpus callosum, (3) pathognomonic chorioretinal lacunae (round, depigmented lesions on fundoscopy)
• Additional features: Cortical malformations (polymicrogyria, heterotopia), vertebral anomalies (hemivertebrae, butterfly vertebrae), microphthalmia, optic nerve colobomas
• EEG: Asynchronous, independent burst-suppression or hypsarrhythmia between hemispheres (reflecting absent corpus callosum); "split brain" pattern
• Prognosis: Severe intellectual disability; drug-resistant epilepsy; median survival to late childhood/early adolescence; some individuals survive into their 30s with aggressive management

References

1. Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1349–1397.
2. Specchio N, Curatolo P. Developmental and epileptic encephalopathies: what we do and do not know. Brain 2021;144(1):32–43.
3. Ohtahara S, Yamatogi Y. Ohtahara syndrome: with special reference to its developmental aspects for differentiating from early myoclonic encephalopathy. Epilepsy Res 2006;70(Suppl 1):S58–S67.
4. Saitsu H, Kato M, Mizuguchi T, et al. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. Nat Genet 2008;40(6):782–788.
5. Weckhuysen S, Mandelstam S, Suls A, et al. KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. Ann Neurol 2012;71(1):15–25.
6. Malerba F, Alberini G, Balagura G, et al. Genotype-phenotype correlations in patients with de novo KCNQ2 pathogenic variants. Neurol Genet 2020;6(6):e528.
7. Mills PB, Struys E, Jakobs C, et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 2006;12(3):307–309.
8. Coughlin CR, Tseng LA, Abdenur JE, et al. Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis 2021;44(1):178–192.
9. Olson HE, Demarest ST, Pestana-Knight EM, et al. Cyclin-dependent kinase-like 5 deficiency disorder: clinical review. Pediatr Neurol 2019;97:18–25.
10. Knight EMP, Bhatt D, Grinspan ZM, et al. Ganaxolone for treatment of CDKL5 deficiency disorder: Marigold study results. Lancet Neurol 2022;21(10):891–901.
11. Barcia G, Fleming MR, Deligniere A, et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat Genet 2012;44(11):1255–1259.
12. McTague A, Howell KB, Cross JH, et al. The genetic landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol 2016;15(3):304–316.
13. Sheidley BR, Malinowski J, Bergner AL, et al. Genetic testing for the epilepsies: a systematic review. Epilepsia 2022;63(2):375–387.
14. Krey I, Platzer K, Esterhuizen A, et al. Current practice in diagnostic genetic testing of the epilepsies. Epileptic Disord 2022;24(5):765–786.
15. Haviland I, Daniels CI, Greene CA, et al. Genetic diagnosis impacts medical management for pediatric epilepsies. Pediatr Neurol 2023;138:71–80.
16. Aicardi J. Aicardi syndrome. Brain Dev 2005;27(3):164–171.
17. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):512–521.
18. Guerrini R, Dravet C. Severe epileptic encephalopathies of infancy, other than West syndrome. In: Epileptic Syndromes in Infancy, Childhood and Adolescence. 6th ed. John Libbey Eurotext; 2019:89–133.